This study is in progress, not accepting new patients
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Lead Scientist at University of California Health
- Joel Hecht (ucla)
Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Bold Therapeutics, Inc.
- Phase 1/2 research study
- Study Type
- About 117 people participating
- Last Updated